Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Sarcoma 1

Conditions

Melanoma 2Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × elesclomol × Clear all
NCT00084214 2014-03-06

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Synta Pharmaceuticals Corp.

Phase 1/2 Completed
103 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00522834 2014-03-04

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Synta Pharmaceuticals Corp.

Phase 3 Terminated
630 enrolled
Dermatologic

Melanoma, Neoplasms

NCT00088088 2008-12-04

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Synta Pharmaceuticals Corp.

Phase 1/2 Completed
86 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00087997 2006-06-20

A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas

Synta Pharmaceuticals Corp.

Phase 2 Completed
80 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡